Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTIMMUNE Extension in Friedreich's Ataxia
NCT02593773Phase 3Completed
- Sponsor
- Amgen
- Start
- Dec 2015
- Primary completion
- Mar 2017
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of interferon gamma-1b in Friedreich's ataxia (FA), sponsored by Amgen. Primary endpoints: Treatment-Emergent Adverse Events at 28 weeks, Neutralizing Antibody and Anti-Drug Antibody Tests at 28 weeks and 1 more. Started Dec 2015; status: completed.
02
Drugs
interferon gamma-1b
03
Conditions
Friedreich's ataxia (FA)
Beyond the preview
Go deeper on NCT02593773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02593773.